In BV2 microglial cells, esketamine suppressed lipopolysaccharide-induced M1 polarization by selectively acting on the NMDAR2A receptor subtype and activating mTOR and BDNF-TrkB signaling.

A query audit of 26 named KEGG signaling pathways in extracellular-vesicle research found that only three PubMed retrievals ...

VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...

Fintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (BMV:RVMD) with an Outperform recommendation. Revolution Medicines, Inc., based in the United States, ...

In 1936 he turned whey, the liquid waste from cheesemaking, into a protein powder. Athletes and gym rats now pay top dollar ...

Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...

Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical ...

UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.

Kazia Therapeutics (KZIA) stock gains new Buy from Gueggenheim, based on company's lead asset paxalisib, following a similar view from Leerink this week. Read more here.

Next-generation CDK 4, CDK 2 and degrader strategies aim to overcome CDK4/6 resistance and reduce toxicity in HR+/HER2− ...

Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...

Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer; Poster ...